Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) Director Cornelius Mccarthy III sold 1,140 shares of Medpace stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the sale, the director directly owned 12,275 shares of the company’s stock, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Medpace Trading Down 2.5%
Shares of MEDP stock opened at $581.95 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a fifty day simple moving average of $533.75 and a two-hundred day simple moving average of $491.74. The stock has a market capitalization of $16.24 billion, a price-to-earnings ratio of 34.11, a P/E/G ratio of 2.66 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Truist Financial increased their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a report on Thursday, July 23rd. Finally, Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $584.18.
Get Our Latest Report on Medpace
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
